Printer Friendly

LEDERLE AND P&G TO CO-PROMOTE ZIAC, FIRST ANTIHYPERTENSIVE DEVELOPED SPECIFICALLY TO ADDRESS DOSE-RELATED SIDE EFFECTS

 WAYNE, N.J., and CINCINNATI, Nov. 22 /PRNewswire/ -- Lederle Laboratories, a division of American Cyanamid Company (NYSE: ACY), and Procter & Gamble Pharmaceuticals (NYSE: PG) today announced a major agreement to co-promote ZIAC(TM) (bisoprolol fumarate/ hydrochlorothiazide), the first antihypertensive drug developed specifically to address the problem of dose-related side effects that may be associated with traditional diuretic and beta-blocker therapy.
 Developed by Lederle, ZIAC is the first beta-blocker/diuretic agent to be marketed as first-line therapy for mild to moderate hypertension. ZIAC offers a beta-blocker and a diuretic in a unique low dose composition to help maximize antihypertensive effectiveness, while minimizing dose-related side effects which may be associated with current treatments, including loss of libido, impotence, or insomnia.
 "ZIAC is composed of the two classes of drugs recently recommended by the National Heart, Lung and Blood Institute's Joint National Committee on Hypertension as preferred initial therapy for hypertension," said Marvin Moser, M.D., clinical professor of medicine at Yale University. "These medications, beta-blockers and diuretics, are the only two classes that have been shown thus far to reduce morbidity and mortality in hypertension in long-term studies."
 Under terms of the agreement, Procter & Gamble Pharmaceuticals and Lederle will share equally in the professional education, continuing research and sales efforts for ZIAC.
 "We're excited about partnering with Lederle on this innovative product which may represent a new and better way for millions of Americans to manage hypertension," said Gil Cloyd, vice president of pharmaceuticals and research and development for P&G. "Partnerships like this are also a key strategy for building P&G's overall health care business. In this case, our partnership will strengthen and advance our progress in the area of cardiovascular drugs."
 "ZIAC reflects Lederle's dedication to providing new therapeutic alternatives for the cardiovascular community," said Edward V. Fritzky, president of Lederle Laboratories. "Our agreement with Procter & Gamble Pharmaceuticals reflects our confidence in their marketing and sales expertise, as demonstrated by the success of their growing health care business."
 Procter & Gamble is one of the fastest growing health care companies in the U.S. P&G makes and markets both prescription and non- prescription products in 60 countries. In prescription drugs, P&G's current focus is in the cardiac, respiratory, anti-infectives and bone health areas. In recent years, P&G has partnered with a range of leading pharmaceutical and biotechnology companies to co-develop and co-promote innovative new therapies.
 Lederle Laboratories, a division of American Cyanamid Company, is a research-intensive organization that manufactures and markets a broad range of products worldwide, including ethical pharmaceuticals, generics and vitamins/nutritionals.
 -0- 11/22/93
 /CONTACT: Jeff Hoyak of Lederle, 201-831-4619, or Kris Burbank of P&G, 513-945-8066/
 (ACY PG)


CO: Lederle Laboratories; American Cyanamid Company; Procter & Gamble
 Pharmaceuticals ST: New Jersey, Ohio IN: MTC SU: PDT


MP-TW -- NY003 -- 6656 11/22/93 08:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1993
Words:472
Previous Article:TMC CORPORATION DEDICATES NEW U.S. HEADQUARTERS IN NORTH BRUNSWICK
Next Article:LADY LUCK RECEIVES FINAL APPROVAL FROM GULFPORT OFFICIALS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters